Pharmaceutical composition for treating liver insulin resistance

Abstract

The invention discloses a pharmaceutical composition for treating liver insulin resistance. The pharmaceutical composition contains a therapeutically-effective amount of 1'-(1H-indazol-5-carbonyl)-1-isopropyl-4,6-dihydrospiro[indazol-5,4'-piperidine]-7(1H)-one and a therapeutically-effective amount of 4-[5-cyano-4-({2-fluoro-4-[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]phenoxy}methyl)-1H-pyrazol-1-yl]piperidin-1-isopropyl formate which have the mass ratio of (3: 1) to (1: 3). Proved by experiments, by using the two kinds of drugs in a combined manner, the liver insulin resistance can be effectively treated, and concomitant symptoms, such as hypertension and diabetes, can be treated while the liver insulin resistance is treated.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating liver insulin resistance. Background technique [0002] Insulin resistance (English: Insulin resistance) refers to a condition in which normal amounts of insulin are insufficient to produce a normal insulin response to fat cells, muscle cells, and liver cells. In adipocytes, insulin resistance leads to hydrolysis of stored triglycerides, which increases plasma free fatty acid levels. In muscle cells, insulin resistance reduces glucose uptake; in hepatocytes, it reduces glucose stores, both leading to elevated blood glucose levels. High insulin and high glucose levels in plasma caused by insulin resistance often lead to metabolic syndrome, gout, and type 2 diabetes. [0003] In a person with a normal metabolism, insulin is secreted by the β-cells in the pancreas after eating, which sends a signal to the insulin-sensing tissues in the body ...

AI Technical Summary

Problems solved by technology

[0012] However, in the prior art, the therapeutic agent for hepatic insulin